Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer

Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer

Prostate Cancer (PCa) is a leading cause of morbidity and mortality among men worldwide. For most men with PCa, their disease will follow an indolent course. However, advanced PCa is associated with poor outcomes. There has been an advent of new therapeutic options with proven efficacy for advanced...

Full description

Bibliographic Details
Main Authors:	Ciara S. McNevin, Anne-Marie Baird, Ray McDermott, Stephen P. Finn
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Series:	Diagnostics
Subjects:	prostate cancer treatment strategies castration-resistant prostate cancer CRPC systemic therapy dynamic classification
Online Access:	https://www.mdpi.com/2075-4418/11/2/345

Similar Items

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
by: Ciara S. McNevin, et al.
Published: (2022-09-01)

Metronomic Chemotherapy in Prostate Cancer
by: Piotr J. Wysocki, et al.
Published: (2022-05-01)

Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan
by: Wei-Chun Weng, et al.
Published: (2022-10-01)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
by: Donald Colbourn
Published: (2012-06-01)

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2016-12-01)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
by: Mike Wenzel, et al.
Published: (2021-04-01)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
by: Takahiro Komori, et al.
Published: (2022-07-01)

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl)
by: Huub H. van Rossum, et al.
Published: (2023-02-01)

Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer
by: Jun A, et al.
Published: (2021-02-01)

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
by: Diana V. Maslov, et al.
Published: (2023-03-01)

A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland
by: Hubert Pakula, et al.
Published: (2017-01-01)

Polygodial, a Sesquiterpene Dialdehyde, Activates Apoptotic Signaling in Castration-Resistant Prostate Cancer Cell Lines by Inducing Oxidative Stress
by: Reshmii Venkatesan, et al.
Published: (2022-10-01)

Zhoushi Qi Ling decoction inhibits the progression of castration-resistant prostate cancer in vivo by regulating macrophage infiltration via IL6-STAT3 signaling
by: Hongwen Cao, et al.
Published: (2024-01-01)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
by: Michele Iuliani, et al.
Published: (2022-09-01)

Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
by: Lena M. Mittlmeier, et al.
Published: (2021-05-01)

MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC
by: Yuanyuan Wang, et al.
Published: (2024-04-01)

Proteomic Landscape of Prostate Cancer: The View Provided by Quantitative Proteomics, Integrative Analyses, and Protein Interactomes
by: Nithin Sadeesh, et al.
Published: (2021-09-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

Pathogenic <i>BRCA</i> Variants as Biomarkers for Risk in Prostate Cancer
by: Ciara S. McNevin, et al.
Published: (2021-11-01)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
by: Jonas S. Heitmann, et al.
Published: (2021-02-01)

Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research
by: Mohammad Waseem, et al.
Published: (2024-01-01)

An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
by: Michael L. Mohler, et al.
Published: (2021-02-01)

Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition
by: Julia Koerner, et al.
Published: (2023-12-01)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
by: Marco Bergamini, et al.
Published: (2022-07-01)

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
by: Daisuke Obinata, et al.
Published: (2023-04-01)

Genetic Suppressor Element 1 (GSE1) Promotes the Oncogenic and Recurrent Phenotypes of Castration-Resistant Prostate Cancer by Targeting Tumor-Associated Calcium Signal Transducer 2 (TACSTD2)
by: Oluwaseun Adebayo Bamodu, et al.
Published: (2021-08-01)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
by: Turco F, et al.
Published: (2022-09-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
by: Pascoe Abigail C, et al.
Published: (2012-03-01)

The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysis
by: Hui Fang, et al.
Published: (2021-06-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
by: Peng Gu, et al.
Published: (2019-06-01)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
by: Nada Lallous, et al.
Published: (2021-06-01)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
by: Masaki Hirabatake, et al.
Published: (2022-05-01)

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ting Bu, et al.
Published: (2022-03-01)

Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials
by: A. E. Smith, et al.
Published: (2022-10-01)

USP54 is a potential therapeutic target in castration-resistant prostate cancer
by: Cheng Zhou, et al.
Published: (2024-02-01)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
by: Yozo Mitsui, et al.
Published: (2023-06-01)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
by: Yan Li, et al.
Published: (2022-10-01)

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro
by: Marvin C. J. Lim, et al.
Published: (2021-12-01)

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
by: Hisham F. Bahmad, et al.
Published: (2022-02-01)